The goal of this randomised controlled trial is to compare the cumulative fluid balance over the first 72 h following inclusion guided by mVExUS versus standard of care in critically ill patients with acute kidney injury receiving CRKT . It will also compare the proportion of CRRT-related complications-including intradialytic hypotension and arrhythmias-between patients managed with mVExUS-guided fluid management and those receiving standard care.
The main questions it aims to answer are:
Does fluid removal rate guided by mVExUS will reduce cumulative fluid balance over the course of the first 72 h of CRRT in ICU patients compared to standard care
Participants will:
Get fluid assessment by mVExUS protocol or a strandard care every 8 hours for 72 hours
Adults (≥ 18 years of age)
Admitted to ICU
Acute kidney injury by KDIGO criteria
Serum potassium ≥ 6.0 mmol/L, or
Refuse to participate
Previous diagnosis of end-stage kidney disease (ESKD) currently on kidney replacement therapy
Kidney transplant recipient
Receive RRT before ICU admission within 90 days